A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
Not Applicable
Completed
- Conditions
- SARS-CoV-2 InfectionCOVID-19
- Interventions
- Biological: Recombinant COVID-19 Vaccine (Sf9 Cell)Biological: COVID-19 Vaccine (Vero Cell), Inactivated
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06381843
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
Phase 3
Recruiting
- Conditions
- COVID-19
- Interventions
- Biological: PlaceboBiological: Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)Biological: Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 4800
- Registration Number
- NCT06175494
- Locations
- 🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination
Phase 3
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- Biological: High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)Biological: control groupBiological: Placebo groupBiological: Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
- First Posted Date
- 2023-06-20
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 4950
- Registration Number
- NCT05911061
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
Phase 2
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- Biological: Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)Biological: Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)
- First Posted Date
- 2023-06-20
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 3100
- Registration Number
- NCT05911048
Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Recombinant COVID-19 vaccine (Sf9 cell)Biological: Recombinant COVID-19 variant vaccine (Sf9 cell)Biological: Recombinant COVID-19 vaccine (CHO cell)
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05770180
- Locations
- 🇨🇳
Jiangsu Provincial Center for Disease Prevention and Control, Nanjing, China
Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05765604
- Locations
- 🇨🇳
Jiangsu Provincial Center for Disease Control, Taizhou, China
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster
Phase 2
Withdrawn
- Conditions
- COVID-19SARS-CoV-2 Infection
- Interventions
- Biological: Viral Vector COVID-19 vaccine (AstraZeneca)Biological: Recombinant COVID-19 variant Vaccine (Sf9 Cell)Biological: mRNA COVID-19 vaccine (Moderna)
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT05465902
- Locations
- 🇲🇽
Clínica de Enfermedades Crónicas y de Procedimientos Especiales, S.C., Morelia, Michoacán De Ocampo, Mexico
A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)
Not Applicable
Completed
- Conditions
- COVID-19SARS-CoV-2 Pneumonia
- Interventions
- Biological: Recombinant COVID-19 vaccine (Sf9 cell)
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT05465785
- Locations
- 🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention, Huai'an, Jiangsu, China
Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
Phase 2
Completed
- Conditions
- SARS-CoV-2 InfectionCOVID-19
- Interventions
- Biological: Recombinant COVID-19 Vaccine (Sf9 Cell)Biological: COVID-19 Vaccine (Vero Cell), Inactivated
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 410
- Registration Number
- NCT05463354
- Locations
- 🇵🇭
Iloilo Doctors Hospital, Iloilo City, Philippines
Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents
Phase 1
Withdrawn
- Conditions
- COVID-19
- Interventions
- Other: Placebo controlBiological: Recombinant COVID-19 vaccine (Sf9 cells)
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- WestVac Biopharma Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT05013983
- Locations
- 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China
© Copyright 2025. All Rights Reserved by MedPath